| NCT ID | NCT05953233 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Viral Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-09-15 |
| Primary Completion | 2029-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-09-15 with a primary completion date of 2029-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized clinical trial is to test the efficacy of high efficiency particulate air (HEPA) cleaners in reducing respiratory viral exposure and infections in elementary school classrooms. Classrooms will be randomized to active vs. sham HEPA cleaners. The main questions it aims to answer are: * Do classroom HEPA cleaners reduce exposure to viruses? * Do classroom HEPA cleaners reduce student and teacher infections? * Do classroom HEPA cleaners reduce infections in family members?
Eligibility Criteria
Inclusion Criteria: Children * Grades K-5 (age 6-12 years) * Attend one of the schools that the study team has permission to obtain classroom/school environmental samples * Have no plans to move schools within the upcoming 12 months * Subject and/or parent guardian must be able to understand and provide informed consent and also willing to participate in the study Adults * Adult (age 21 or older) parent, caretaker, or household member of child participating in this study, or teacher in classroom participating in study * Able to understand and provide informed consent Exclusion Criteria: Children * Contraindication to or inability to participate in home self-collection of nasal swab samples * Severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility) * Severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance * Families who do not speak English or Spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures Adults * Contraindication to or inability to participate in home self-collection of nasal swab samples * Severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility) * Severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance * Families who do not speak English or Spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05953233 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 90 Years, studying Viral Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05953233 currently recruiting?
Yes, NCT05953233 is actively recruiting participants. Contact the research team at plai@mgh.harvard.edu for enrollment information.
Where is the NCT05953233 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05953233 clinical trial?
NCT05953233 is sponsored by Massachusetts General Hospital. The trial plans to enroll 200 participants.